Previous human and animal studies have demonstrated that telmisartan, an ARB and a partial agonist of peroxisome proliferator-activated receptor gamma (PPAR-γ), can improve obesity related cardiometabolic sequels in obesity hypertension [19, 20]. Here, PPARG is linked to obesity disorder.